Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
Vaccinations and immunisations
HIV-Related Factors Predict Reinforced Hepatitis B Vaccination Success

Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination, according to an article published in Vaccine.

Published
03 June 2019
From
Infectious Disease Advisor
Hepatitis and HIV
Summary from CROI 2019 for viral Hepatitis, from Jürgen Rockstroh

Although no new drugs for HBV or HCV therapy were presented a whole range of important clinical studies were discussed which all have important clinical implications for daily practice.

Published
09 April 2019
From
NATAP
Hepatitis B
Demand for Hepatitis B Vaccines to Soar from End-use Industries and Push Revenues in the Global Market

The global market for hepatitis B vaccine is growing at a significant rate due to increasing number of cases with hepatitis B infection. In addition, growing population and growing awareness for improved healthcare facilities is increasing the global market for hepatitis B vaccine.

Published
02 April 2019
From
New Daily Herald
Hepatitis B
Hepatitis B Virus Elevates Risk for Age-Related Macular Degeneration

Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration (AMD), according to a new report. It’s possible that hepatitis B virus may even accelerate the progression of AMD.

Published
14 March 2019
From
MD Magazine
Cancer
Undiagnosed HBV, HCV, HIV prevalent in newly diagnosed cancer cases

Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

Published
18 January 2019
From
Healio
Hepatitis B
Advanced fibrosis found in one-third of patients with HIV/HBV coinfection

Researchers observed significant fibrosis in more than one-third of patients with hepatitis B and HIV coinfection undergoing long-term combination antiretroviral therapy with viral suppression, according to a study published in American Journal of Gastroenterology.

Published
03 January 2019
From
Healio
Hepatitis C treatment
Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

Published
15 October 2018
From
Healio
Hepatitis B
$20 blood test could help diagnose hepatitis B patients across Africa

Researchers have developed an accurate diagnostic score that consists of inexpensive blood tests to identify patients who require immediate treatment against the deadly hepatitis B virus -- which can lead to liver damage or cancer.

Published
02 July 2018
From
Science Daily
Hepatitis B
'Virus-cracking' molecules advance fight against hepatitis B

Researchers have found that certain molecules -- currently under clinical trial -- are able to 'crack' the protective shell of the hepatitis B virus, suggesting it may be possible to attack the virus after it has already taken hold in the body.

Published
07 February 2018
From
Science Daily
Hepatitis B
Gilead's hepatitis B therapy to vie with 20 Korean therapies

Korea has approved 20 products made by Korean companies targeting for No.1 chronic hepatitis B therapy Viread (compound: tenofovir disoproxil fumarate) made by Gilead.

Published
14 August 2017
From
Korea Biomedical Review
← First12345...10Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.